Supernus Pharmaceuticals, Inc. $SUPN Shares Bought by Cwm LLC

Core Insights - Cwm LLC increased its holdings in Supernus Pharmaceuticals by 92.4% in Q2, owning 3,080 shares valued at $97,000 [2] - Other institutional investors also adjusted their stakes, with notable increases from GAMMA Investing LLC (116.7% increase) and State of Wyoming (58.8% increase) [3] - Insider trading activity included CEO Jack A. Khattar selling 140,000 shares for approximately $5.88 million, reducing his ownership by 11.96% [4] Institutional Holdings - Cwm LLC's investment grew to 3,080 shares after acquiring an additional 1,479 shares in Q2 [2] - Caitong International Asset Management and BI Asset Management both acquired new stakes in Q1, valued at approximately $41,000 and $46,000 respectively [3] - State of Wyoming increased its holdings to 4,754 shares, worth $156,000 after buying 1,761 additional shares [3] Insider Activity - CEO Jack A. Khattar sold 140,000 shares at an average price of $42.02, totaling $5,882,800, leaving him with 1,030,183 shares valued at approximately $43.29 million [4] - SVP Frank Mottola sold 14,000 shares at an average price of $44.51, resulting in a total transaction of $623,140 and a 47.46% decrease in ownership [4] - In the last three months, insiders sold 362,741 shares valued at $16.39 million, with insiders owning 8.80% of the stock [4] Stock Performance - Supernus Pharmaceuticals shares opened at $55.13, with a market capitalization of $3.09 billion and a P/E ratio of 47.94 [5] - The stock has a 1-year low of $29.16 and a high of $57.65, with a fifty-day moving average of $48.02 [5] Analyst Ratings - Bank of America initiated coverage with a "buy" rating and a target price of $65.00 [6] - Cantor Fitzgerald raised its price target from $46.00 to $63.00, maintaining an "overweight" rating [6] - The consensus rating for Supernus Pharmaceuticals is "Buy" with an average target price of $63.25 [6] Company Overview - Supernus Pharmaceuticals focuses on developing and commercializing products for central nervous system diseases [8] - Key products include Trokendi XR for epilepsy and migraine prophylaxis, and Oxtellar XR for partial onset seizures [8]